Study Summary
This trial is testing whether low levels of oxygen in the tumor (hypoxia) play a role in prostate cancer.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 3 Secondary · Reporting Duration: after follow up is completed
after follow is completed
To determine the relationship between pre-treatment tumor oxygen levels and the subsequent development of metastases and androgen-resistant prostate cancer.
after follow up is completed
To determine the relationship between pre-treatment tumor oxygen levels and mutations of the p53 gene, and the impact of this interaction on patient outcome.
To determine whether androgen ablation overcomes any adverse effect of hypoxia on outcome.
after follow-up is completed
To determine the relationship between pre-treatment prostate cancer oxygen levels and long-term disease control following treatment with radiotherapy, and the independent prognostic effect of oxygen measurements.
To evaluate oxygen levels in clinically localized prostate cancer prior to treatment.
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
1 Treatment Group
hypoxia and RT in prostate cancer
1 of 1
Experimental Treatment
195 Total Participants · 1 Treatment Group
Primary Treatment: Pre-treatment tumour oxygen measurements · No Placebo Group · Phase 2
hypoxia and RT in prostate cancer
Procedure
Experimental Group · 1 Intervention: Pre-treatment tumour oxygen measurements · Intervention Types: ProcedureTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: after follow up is completed
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,382 Previous Clinical Trials
473,280 Total Patients Enrolled
63 Trials studying Prostate Cancer
15,372 Patients Enrolled for Prostate Cancer
Princess Margaret Hospital, CanadaOTHER
114 Previous Clinical Trials
29,893 Total Patients Enrolled
8 Trials studying Prostate Cancer
1,516 Patients Enrolled for Prostate Cancer
U.S. Army Medical Research and Development CommandFED
278 Previous Clinical Trials
244,538 Total Patients Enrolled
Michael Milosevic, MDPrincipal InvestigatorPrincess Margaret Hospital, Canada
10 Previous Clinical Trials
953 Total Patients Enrolled
Eligibility Criteria
Age 18 - 80 · Male Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You have not received hormonal or cytotoxic anti-cancer therapy prior to study entry.
You can understand the English language.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments